Trial · NCT01041274
DECIFER: Depression and Citalopram In First Episode Recovery
NCT01041274, Phase 4, Completed, NYU Langone Health; results first posted 2018-11-16
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. DECIFER: Depression and Citalopram In First Episode Recovery. Trials, record NCT01041274. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01041274
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DECIFER: Depression and Citalopram In First Episode Recovery
- NCT number
- NCT01041274
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 95 participants, actual
- Lead sponsor
- NYU Langone Health
- Conditions
- Schizophrenia, Schizophreniform Disorder
- Interventions
- Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
- First posted
- 2009-12-31
- Last updated
- 2019-12-17
- Results first posted
- 2018-11-16
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Calgary Depression Scale for Schizophrenia (CDSS) | Screening, Baseline, Weeks 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 | The Calgary Depression Scale for Schizophrenia (CDSS) is a rater-administered assessment that measures depression in schizophrenia. The scale consists of 9 questions each rated 0 to 3. 0 corresponds with "absent" and 3 corresponds with "severe". The total score for all items is provided for each time point. The minimum score is 0 and the maximum score is 27. A higher score indicates increased depressive symptoms. |
| Secondary | Scale for the Assessment of Negative Symptoms (SANS) | Screening, Baseline, Weeks 4, 8, 12, 16, 20, 24, 28,32, 36, 40, 44, 48, 52 | The Scale for the Assessment of Negative Symptoms (SANS) is a 25-item rater-administered scale to assess negative symptoms in schizophrenia. Each item is rated from 0 to 5 where 0 is "none" and 5 is "severe". The SANS consists of five subscales: affective flattening/blunting, alogia, avolition/apathy, ahnedonia/asociality, and attention. Each subscale contains a "global rating" item which assesses the overall severity of symptoms within the subscale. The total score consists of a sum of all items except the global ratings and items 10, 23, 24, and 25. The total score is reported for each time point. The minimum total score is 0 and the maximum total score is 85. A higher score indicates increased severity of negative symptoms. |
| Secondary | Brief Psychiatric Rating Scale (BPRS) | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 | The Brief Psychiatric Rating Scale (BPRS) is a 24-item rater-administered scale assessing overall psychiatric and psychotic symptoms. Items 1-14 are assessed through self-report and items 15-24 are assessed on the basis of observed behavior. Each item is rated from 1 to 7 where 1 is "not present" and 7 is "extremely severe". A score of 0 indicates "not assessed". The total score is a sum of all items and is reported for each time point. The minimum score is 24 and the maximum score is 168, and higher values indicate increased symptom severity. |
| Secondary | InterSePT Scale for Suicidal Thinking (ISST) | Screening, Baseline, Weeks 1-8 | IntraSePT Scale for Suicidal Thinking (ISST) consists of 12 questions rated from 0 to 2 with increasing intensity (i.e. none, weak, moderate to stron). It quantifies the current conscious and overtly expressed suicidal thinking in schizophrenic patients by canvassing various suicidal thoughts and wishes during a 20- to 30-min semi-structured interview. The total score is computed by adding the 12 individual item scores and ranges from 0 to 24. A score of zero indicates low suicidal ideation and a score of 24 indicates high suicidal ideation. |
| Secondary | Heinrich Quality of Life Scale (QOL) | Baseline, Week 4, 8, 12, 16, 20, 24, 32, 40, 52 | The Quality of Life Scale (QOL) is a 21-item scale based on a semi-structured interview to assess functional deficits in schizophrenia. Each item is rated on a 7-point scale where 0 indicates a normal level of functioning, or no deficit, and 6 corresponds to more severe deficit. The total score is a sum of all items. The minimum total score is 0 and the maximum total score is 126, higher scores indicate increased impairment in functioning. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Calgary Depression Scale for Schizophrenia (CDSS) | Screening, Baseline, Weeks 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 | Not all participants completed the CDRS assessment at each time point. Results are reported for all participants who completed the CDRS assessment. | units on a scale | MEAN |
| SECONDARY | Scale for the Assessment of Negative Symptoms (SANS) | Screening, Baseline, Weeks 4, 8, 12, 16, 20, 24, 28,32, 36, 40, 44, 48, 52 | Not all participants completed the SANS assessment at each time point. Results are reported for all participants who completed the SANS assessment. | units on a scale | MEAN |
| SECONDARY | Brief Psychiatric Rating Scale (BPRS) | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 | Not all participants completed the BPRS assessment at each time point. Results are reported for all participants who completed the BPRS assessment. | units on a scale | MEAN |
| SECONDARY | InterSePT Scale for Suicidal Thinking (ISST) | Screening, Baseline, Weeks 1-8 | Given the low scores on this assessment, data collection was discontinued. | score on a scale | MEAN |
| SECONDARY | Heinrich Quality of Life Scale (QOL) | Baseline, Week 4, 8, 12, 16, 20, 24, 32, 40, 52 | Not all participants completed the QOL assessment at each time point. Results are reported for all participants who completed the QOL assessment. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group140
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Calgary Depression Scale for Schizophrenia (CDSS) | Citalopram | Screening | 1.93 | Standard Deviation 1.74 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Placebo | Screening | 2.26 | Standard Deviation 1.74 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Citalopram | Baseline | 1.83 | Standard Deviation 1.79 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Placebo | Baseline | 2.58 | Standard Deviation 2.99 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Citalopram | Week 1 | 2.13 | Standard Deviation 2.47 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Placebo | Week 1 | 1.94 | Standard Deviation 3.03 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Citalopram | Week 2 | 2.00 | Standard Deviation 2.34 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Placebo | Week 2 | 1.84 | Standard Deviation 2.53 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Citalopram | Week 3 | 2.4 | Standard Deviation 2.80 | units on a scale |
| Calgary Depression Scale for Schizophrenia (CDSS) | Placebo | Week 3 | 1.87 | Standard Deviation 2.53 | units on a scale |
1 to 10 of 140Source ClinicalTrials.gov
See all 140 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Citalopram | 49 | |
| Overall Study | STARTED | Placebo | 46 | |
| Overall Study | COMPLETED | Citalopram | 26 | |
| Overall Study | COMPLETED | Placebo | 25 | |
| Overall Study | NOT COMPLETED | Citalopram | 23 | |
| Overall Study | NOT COMPLETED | Placebo | 21 |
Source ClinicalTrials.gov
Adverse events100
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pneumonia | Infections and infestations | Citalopram | 1 | 49 | 1 |
| other | Pneumonia | Infections and infestations | Placebo | 0 | 46 | 0 |
| other | Akathisia | Nervous system disorders | Citalopram | 1 | 49 | 1 |
| other | Akathisia | Nervous system disorders | Placebo | 1 | 46 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Citalopram | 0 | 49 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Placebo | 1 | 46 | 1 |
| other | Anorgasmia | Reproductive system and breast disorders | Citalopram | 1 | 49 | 1 |
| other | Anorgasmia | Reproductive system and breast disorders | Placebo | 1 | 46 | 1 |
| other | Apathy | Psychiatric disorders | Citalopram | 1 | 49 | 1 |
| other | Apathy | Psychiatric disorders | Placebo | 2 | 46 | 2 |
1 to 10 of 100Source ClinicalTrials.gov
See all 100 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Citalopram | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Citalopram | 22 | 49 |
| Total, other adverse events | Placebo | 18 | 46 |
| Total, serious adverse events | Citalopram | 5 | 49 |
| Total, serious adverse events | Placebo | 4 | 46 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33814546 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH084900 | Citalopram in First Episode Schizophrenia | GOFF, DONALD C. | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NATIONAL INSTITUTE OF MENTAL HEALTH | 2009 to 2013 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Citalopram vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01041274
GET https://conductscience.org/api/trials/v1/NCT01041274/results?page=2